Walk into any dispensary in America and you will encounter the same classification system: indica for relaxation, sativa for energy, hybrid for something in between. It is the most widely used framework in cannabis retail, repeated by budtenders thousands of times per day, printed on packaging, and embedded in every strain database on the internet.

It is also, according to a growing body of genomic and chemical research, largely meaningless.

The Origin of a Taxonomy

The indica/sativa distinction dates to the 18th century, when European botanists classified cannabis plants by their physical characteristics. Cannabis sativa, described by Carl Linnaeus in 1753, referred to tall, narrow-leafed plants cultivated in Western Eurasia for fiber and seeds. Cannabis indica, described by Jean-Baptiste Lamarck in 1785, referred to shorter, broad-leafed plants from India used for their psychoactive properties.

This was a botanical classification based on plant morphology — how the plant looks, not how it makes you feel. The leap from “short plant with wide leaves” to “this will relax you” happened not in a laboratory but in the marketing departments of dispensaries and seed companies during the early decades of legalization.

What Genomics Revealed

A landmark 2021 study published in Nature Plants analyzed the genomes of 297 cannabis cultivars, including samples marketed as indica, sativa, and hybrid. The researchers found that genetic ancestry — the actual evolutionary lineage of the plants — showed little correlation with the indica/sativa labels assigned by the cannabis industry.

Strains labeled “indica” were frequently more genetically similar to strains labeled “sativa” than to other strains also labeled “indica.” The labels had become so muddled through decades of crossbreeding, relabeling, and informal classification that they contained almost no reliable genetic information.

A 2022 follow-up study from Dalhousie University went further, analyzing the chemical profiles of over 800 cannabis samples. The conclusion was unambiguous: indica and sativa labels were not meaningful predictors of chemical composition. Two strains both labeled “indica” could have dramatically different cannabinoid and terpene profiles, while an “indica” and a “sativa” could be chemically near-identical.

What Actually Determines Your Experience

If the label on the jar does not predict the experience, what does? The research points to three factors, in order of importance:

Cannabinoid ratios. The ratio of THC to CBD is the single strongest predictor of subjective effects. High-THC, low-CBD strains produce more intense psychoactive effects regardless of indica/sativa designation. Strains with balanced THC:CBD ratios (1:1 or 2:1) tend to produce calmer, less anxious experiences. Strains with high CBD and minimal THC produce no psychoactive high at all.

Terpene profiles. Terpenes are aromatic compounds produced by the cannabis plant that are increasingly understood to modulate the cannabis experience. Myrcene, the most common cannabis terpene, appears to enhance sedation. Limonene is associated with mood elevation. Linalool has documented anxiolytic properties. Beta-caryophyllene binds directly to CB2 receptors and may reduce inflammation.

Your own biology. Individual variation in CB1 receptor density, endocannabinoid tone, liver enzyme activity (which affects how THC is metabolized), and prior cannabis experience all influence how any given strain affects you. This is why two people can consume the same product and report meaningfully different experiences.

The Industry’s Slow Pivot

The cannabis industry is beginning to acknowledge what the science has shown. Leafly, the largest cannabis strain database, introduced a new classification system in 2023 based on chemical profiles rather than indica/sativa taxonomy. Several state regulators are discussing whether to require terpene profile labeling alongside potency testing.

But change is slow. The indica/sativa framework is deeply embedded in consumer expectations, dispensary training programs, and product marketing. Many industry participants privately acknowledge the labels are scientifically meaningless while continuing to use them because consumers expect them.

A Better Framework

The emerging consensus among cannabis researchers — supported by clinical evidence for the entourage effect — is that consumers should evaluate cannabis products based on three data points: THC percentage, CBD percentage, and dominant terpenes. A product labeled “indica” with 28% THC, 0% CBD, and dominant terpinolene will feel nothing like another “indica” with 18% THC, 2% CBD, and dominant myrcene.

Use the interactive strain experience predictor below to see how cannabinoid ratios and terpene profiles — not indica/sativa labels — actually map to subjective effects. Enter a strain’s lab data and see what the chemistry predicts about your likely experience.

The bottom line: stop shopping by label. Start shopping by data. Browse our strain database to compare cultivars by their actual chemical profiles rather than outdated labels. Your dispensary receipt may still say “indica” or “sativa,” but the compounds in the product are what your brain actually responds to — and those compounds do not care what category marketing has assigned them.